ARMP
Armata Pharmaceuticals, Inc. AMEX Listed May 20, 1994$3.74
+3.31%
vs $3.62
Mkt Cap $137.3M
52w Low $2.94
6.0% of range
52w High $16.34
50d MA $4.84
200d MA $7.38
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-1.3x
ROE
79.5%
P/FCF
-5.2x
RSI (14)
18.70
ATR (14)
$0.55
Beta
1.40
50d MA
$4.84
200d MA
$7.38
Avg Volume
284.3K
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
4503 Glencoe Avenue · Marina del Rey, CA 90292 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | AMC | -0.48 | -0.27 | +43.8% | 4.31 | +0.2% | +11.8% | -5.4% | -1.8% | +1.8% | +11.2% | — |
| May 13, 2026 | AMC | -0.38 | -3.16 | -731.6% | 8.82 | -1.4% | -7.0% | -1.8% | -5.6% | +11.3% | -4.0% | — |
| Mar 25, 2026 | AMC | -0.19 | -0.51 | -168.4% | 8.61 | -5.8% | +8.6% | -10.5% | +2.6% | +19.2% | +3.1% | — |
| Nov 12, 2025 | AMC | -0.42 | -0.42 | +0.0% | 6.69 | -5.2% | -4.6% | +14.7% | -8.3% | +2.5% | +6.1% | — |
| Aug 12, 2025 | AMC | -0.39 | -0.32 | +17.9% | 2.46 | +3.7% | +1.6% | +1.2% | +0.8% | +2.4% | -2.7% | — |
| May 14, 2025 | AMC | -0.38 | -0.20 | +47.4% | 1.38 | +0.0% | +1.4% | -3.6% | +75.6% | -5.1% | -6.7% | — |
| Mar 20, 2025 | AMC | -0.35 | -0.23 | +34.3% | 2.01 | -1.0% | -10.9% | +2.8% | -8.7% | -1.8% | +0.0% | — |
| Nov 13, 2024 | AMC | -0.28 | -0.15 | +46.4% | 2.72 | +0.4% | -1.5% | -10.1% | -7.1% | -11.6% | +5.6% | — |
| Aug 13, 2024 | AMC | -0.52 | -0.65 | -25.0% | 2.71 | -2.6% | -10.7% | +0.8% | -7.0% | +3.1% | +1.3% | — |
| May 7, 2024 | AMC | -0.28 | -0.69 | -146.4% | 2.86 | -1.4% | -3.5% | +18.1% | -5.2% | +3.9% | -9.0% | — |
| Mar 21, 2024 | AMC | -0.35 | -0.55 | -57.1% | 3.69 | +0.8% | +1.4% | +4.5% | +3.3% | +1.5% | +2.0% | — |
| Nov 14, 2023 | AMC | -0.33 | -0.31 | +6.1% | 2.68 | +4.1% | -19.8% | -6.5% | +10.4% | -0.9% | -3.2% | — |
| Aug 14, 2023 | AMC | -0.35 | -0.28 | +20.0% | 4.16 | -1.9% | +3.4% | -6.7% | -1.7% | -9.6% | +1.4% | — |
| May 11, 2023 | AMC | -0.29 | -0.40 | -37.9% | 1.30 | +0.0% | -3.8% | +8.8% | +2.2% | -10.1% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.73 | $8.78 | +0.6% | +9.3% | +24.3% | -10.4% | +1.9% | -0.6% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.17 | -13.3% | +75.6% | -5.1% | -6.7% | -11.0% | +1.1% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.98 | +1.5% | +1.5% | -1.5% | -0.5% | +5.2% | -1.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.73 | +0.4% | -1.5% | -10.1% | -7.1% | -11.6% | +5.6% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $2.23 | -0.9% | +22.2% | -1.1% | -1.5% | -10.1% | -7.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.42 | +0.0% | +0.8% | -7.0% | +3.1% | +1.3% | -3.4% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.78 | +3.7% | +11.9% | +5.0% | -7.9% | +2.8% | +10.7% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.86 | $2.82 | -1.4% | -3.5% | +18.1% | -5.2% | +3.9% | -9.0% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.69 | $3.72 | +0.8% | +1.4% | +4.5% | +3.3% | +1.5% | +2.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.35 | $4.47 | +2.8% | -4.4% | +3.4% | -6.7% | -1.7% | -9.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.30 | $1.30 | +0.0% | -3.8% | +8.8% | +2.2% | -10.1% | +4.0% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.75 | $1.75 | +0.0% | +8.6% | -7.9% | -8.0% | +2.5% | -6.1% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.06 | $2.97 | -2.9% | -13.1% | -17.3% | -5.0% | -5.7% | -4.6% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.33 | $5.99 | +12.4% | -0.2% | -0.9% | +4.4% | -6.5% | -4.9% |
| May 15 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.98 | $2.98 | +0.1% | +4.0% | +2.9% | -1.3% | +0.3% | -2.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $2.98 | +0.1% | +4.0% | +2.9% | -1.3% | +0.3% | -2.8% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.89 | +5.1% | +0.0% | +5.5% | -2.8% | +20.2% | -3.2% |
| Mar 20 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.75 | $2.89 | +5.1% | +0.0% | +5.5% | -2.8% | +20.2% | -3.2% |
| Feb 6 | Maxim Group | Maintains | Buy → Buy | — | $3.71 | $3.84 | +3.5% | -2.7% | +10.0% | +1.8% | -1.0% | +4.2% |
| Jun 19 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $2.86 | $2.95 | +3.1% | +17.5% | -6.8% | -11.2% | +24.1% | +4.3% |
No insider trades available.
8-K · 8.01
!! High
Armata Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 23
8-K · 7.01
! Medium
Armata Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 14
8-K · 7.01
! Medium
Armata Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Armata Pharmaceuticals is advancing its multi-phage therapeutic toward a Phase 3 study for treating complicated bacteremia, representing clinical progress toward potential market approval and revenue generation.
Jul 20
8-K · 5.02
!!! Very High
Armata Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Armata Pharmaceuticals appointed David House as CFO while he resigned from the board, effective July 17, 2026, signaling potential leadership restructuring at the biopharmaceutical company.
Jul 20
8-K · 7.01
! Medium
Armata Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Armata Pharmaceuticals received FDA agreement on a pediatric study plan for AP-SA02, expanding its potential market for treating Staphylococcus aureus bacteremia in children and establishing a clear regulatory pathway forward.
Jul 13
8-K · 8.01
!! High
Armata Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 23
8-K · 5.02
!!! Very High
Armata Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Armata Pharmaceuticals appointed Dr. Daniel Gilmer as a director, expanding its board to strengthen governance and potentially bring specialized expertise to guide the company's pharmaceutical development strategy.
Apr 27
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Armata's advance notice bylaw deadline for shareholder proposals and nominations is approaching; investors should monitor whether meaningful governance challenges or director contests emerge before the cutoff.
Apr 2
8-K
Unknown — 8-K Filing
Armata's grant revenue in Q4 2025 suggests continued external funding for its bacteriophage program, reducing near-term cash burn concerns, though investors should monitor clinical trial progress and path to profitability.
Mar 25
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Armata Pharmaceuticals disclosed material information via 8-K filing on March 19, 2026, though specific details aren't provided—investors should review the full disclosure to assess impact on clinical progress, partnerships, or financial position.
Mar 19
8-K · 7.01
! Medium
Armata Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Armata Pharmaceuticals received FDA Qualified Infectious Disease Product designation for AP-SA02, potentially accelerating development timelines and providing regulatory advantages for this bacteremia treatment candidate.
Feb 23
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Madison Asset Management, Llc | 2,107,175 | $14M | New | Jun 2026 |
| 2 | Blackrock, Inc. | 559,986 | $4M | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 487,968 | $3M | Added | Jun 2026 |
| 4 | Millennium Management Llc | 470,500 | $3M | Added | Jun 2026 |
| 5 | Dauntless Investment Group, Llc | 203,891 | $1M | Added | Jun 2026 |
| 6 | Edgewood Management Llc | 100,000 | $1M | — | Mar 2026 |
| 7 | Susquehanna International Group, Llp | 64,759 | $663K | Added | Mar 2026 |
| 8 | Informed Momentum Co Llc | 60,955 | $624K | New | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 81,354 | $527K | New | Jun 2026 |
| 10 | Grey Ledge Advisors, Llc | 50,000 | $324K | New | Jun 2026 |
| 11 | Renaissance Technologies Llc | 48,318 | $313K | Added | Jun 2026 |
| 12 | Qube Research & Technologies Ltd | 26,628 | $273K | Added | Mar 2026 |
| 13 | Seacrest Wealth Management, Llc | 41,524 | $269K | — | Jun 2026 |
| 14 | Northern Trust Corp | 24,646 | $252K | — | Mar 2026 |
| 15 | Captrust Financial Advisors | 13,140 | $135K | — | Mar 2026 |
| 16 | Bank Of America Corp /de/ | 11,714 | $120K | Added | Mar 2026 |
| 17 | Hrt Financial Lp | 10,595 | $108K | New | Mar 2026 |
| 18 | Jane Street Group, Llc | 17,153 | $108K | New | Dec 2025 |
| 19 | Nuveen, Llc | 15,905 | $103K | New | Jun 2026 |
| 20 | Rhumbline Advisers | 8,453 | $55K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 16
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 58,264 | $627K | Feb 2026 |
| 2 | Ultra-Small Company Market Fund | 41,382 | $424K | Mar 2026 |
| 3 | iShares Micro-Cap ETF | 27,051 | $277K | Mar 2026 |
| 4 | Fidelity Total Market Index Fund | 17,296 | $141K | May 2026 |
| 5 | Fidelity Series Total Market Index Fund | 16,271 | $133K | May 2026 |
| 6 | LVIP State Street Small-Cap Index Fund | 9,700 | $63K | Jun 2026 |
| 7 | Small Cap Index Fund | 6,118 | $40K | Jun 2026 |
| 8 | Small-Cap Index Portfolio | 3,826 | $25K | Jun 2026 |
| 9 | DWS Small Cap Index VIP | 1,840 | $12K | Jun 2026 |
| 10 | CVT Russell 2000 Small Cap Index Portfolio | 1,076 | $7K | Jun 2026 |
| 11 | Victory Extended Market Index Fund | 1,017 | $7K | Jan 2026 |
| 12 | PD Small-Cap Growth Index Portfolio | 1,044 | $7K | Jun 2026 |
| 13 | Nationwide Small Cap Index Fund | 1,178 | $5K | Jul 2026 |
| 14 | ULTRA SMALL CAP PROFUND | 153 | $695 | Jul 2026 |
| 15 | SMALL-CAP PROFUND | 10 | $45 | Jul 2026 |
| 16 | Russell 2000(R) 1.5x Strategy Fund | 3 | $19 | Jun 2026 |
Valuation
Market Cap
$137.3M
Enterprise Value
$383.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
—
P/S
41.62x
P/FCF
-5.15x
EV/EBITDA
—
Shares Out
36.2M
Financials (TTM)
Revenue
$3.3M
Net Income
-$192.2M
EBITDA
-$169.0M
Free Cash Flow
-$26.3M
Op Cash Flow
-$25.8M
EPS Basic
$-4.80
EPS Diluted
$-7.59
EPS Forward
$-1.15
Gross Margin
68.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$76.9M
Total Liab.
$295.5M
Total Equity
-$218.6M
Cash
$8.7M
LT Debt
$256.9M
Book Value/Sh
$-6.03
Debt/Equity
-1.32x
Current Ratio
1.19
Quick Ratio
1.19
Returns & Growth
ROE
79.5%
ROA
-226.1%
ROIC
-43.1%
Rev Growth YoY
-5.2%
EPS Growth YoY
-817.6%
Price Returns
2W
-30.5%
1M
-31.4%
3M
-49.5%
6M
-60.0%
12M
+24.3%
Technicals
52W High
$16.34
52W Low
$2.94
50d MA
$4.84
200d MA
$7.38
RSI (14)
18.70
ATR (14)
$0.55
Beta
1.40
Avg Volume
284K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.00
High
$15.00
Low
$15.00
Median
$15.00
Data updated apr 24, 2026 6:57pm
· Source: financialmodelingprep.com